Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2025 08:45 ET | Source: Windward Bio

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical...